5 quarters tracked · Beat rate 80% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.76 | $0.78 | +2.1% | Beat |
| Q1 2026 | 2026-03-31 | $0.75 | $0.78 | +4.2% | Beat |
| Q4 2025 | 2025-12-31 | $0.64 | $0.58 | -8.8% | Miss |
| Q3 2025 | 2025-09-30 | $0.61 | $0.67 | +9.6% | Beat |
| Q2 2025 | 2025-06-30 | $0.64 | $0.67 | +4.4% | Beat |
Earnings Beat Rate
Edwards Lifesciences has beaten analyst EPS estimates in 4 of 5 tracked quarters (80% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →